208 related articles for article (PubMed ID: 26168167)
1. A Mutation in the Carbohydrate Recognition Domain Drives a Phenotypic Switch in the Role of Galectin-7 in Prostate Cancer.
Labrie M; Vladoiu M; Leclerc BG; Grosset AA; Gaboury L; Stagg J; St-Pierre Y
PLoS One; 2015; 10(7):e0131307. PubMed ID: 26168167
[TBL] [Abstract][Full Text] [Related]
2. Cytosolic galectin-7 impairs p53 functions and induces chemoresistance in breast cancer cells.
Grosset AA; Labrie M; Gagné D; Vladoiu MC; Gaboury L; Doucet N; St-Pierre Y
BMC Cancer; 2014 Nov; 14():801. PubMed ID: 25367122
[TBL] [Abstract][Full Text] [Related]
3. X-ray structure of a protease-resistant mutant form of human galectin-8 with two carbohydrate recognition domains.
Yoshida H; Yamashita S; Teraoka M; Itoh A; Nakakita S; Nishi N; Kamitori S
FEBS J; 2012 Oct; 279(20):3937-51. PubMed ID: 22913484
[TBL] [Abstract][Full Text] [Related]
4. The second glutamic acid in the C-terminal CRD affects the carbohydrate-binding properties of recombinant galectins of Haemonchus contortus.
Wang J; Yan R; Xu L; Li X
Vet Parasitol; 2007 Sep; 148(3-4):247-55. PubMed ID: 17643820
[TBL] [Abstract][Full Text] [Related]
5. Complex N-glycans are the major ligands for galectin-1, -3, and -8 on Chinese hamster ovary cells.
Patnaik SK; Potvin B; Carlsson S; Sturm D; Leffler H; Stanley P
Glycobiology; 2006 Apr; 16(4):305-17. PubMed ID: 16319083
[TBL] [Abstract][Full Text] [Related]
6. Intracellular galectin-7 expression in cancer cells results from an autocrine transcriptional mechanism and endocytosis of extracellular galectin-7.
Bibens-Laulan N; St-Pierre Y
PLoS One; 2017; 12(11):e0187194. PubMed ID: 29117220
[TBL] [Abstract][Full Text] [Related]
7. Galectin-3 in Prostate Cancer Stem-Like Cells Is Immunosuppressive and Drives Early Metastasis.
Caputo S; Grioni M; Brambillasca CS; Monno A; Brevi A; Freschi M; Piras IS; Elia AR; Pieri V; Baccega T; Lombardo A; Galli R; Briganti A; Doglioni C; Jachetti E; Bellone M
Front Immunol; 2020; 11():1820. PubMed ID: 33013832
[TBL] [Abstract][Full Text] [Related]
8. Galectin-8 tandem-repeat structure is essential for T-cell proliferation but not for co-stimulation.
Cattaneo V; Tribulatti MV; Campetella O
Biochem J; 2011 Feb; 434(1):153-60. PubMed ID: 21091438
[TBL] [Abstract][Full Text] [Related]
9. The N- and C-terminal carbohydrate recognition domains of Haemonchus contortus galectin bind to distinct receptors of goat PBMC and contribute differently to its immunomodulatory functions in host-parasite interactions.
Lu M; Tian X; Yang X; Yuan C; Ehsan M; Liu X; Yan R; Xu L; Song X; Li X
Parasit Vectors; 2017 Sep; 10(1):409. PubMed ID: 28870237
[TBL] [Abstract][Full Text] [Related]
10. A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease.
Laderach DJ; Gentilini LD; Giribaldi L; Delgado VC; Nugnes L; Croci DO; Al Nakouzi N; Sacca P; Casas G; Mazza O; Shipp MA; Vazquez E; Chauchereau A; Kutok JL; Rodig SJ; Elola MT; Compagno D; Rabinovich GA
Cancer Res; 2013 Jan; 73(1):86-96. PubMed ID: 23108139
[TBL] [Abstract][Full Text] [Related]
11. Treatment of prostate carcinoma with (galectin-3)-targeted HPMA copolymer-(G3-C12)-5-Fluorouracil conjugates.
Yang Y; Zhou Z; He S; Fan T; Jin Y; Zhu X; Chen C; Zhang ZR; Huang Y
Biomaterials; 2012 Mar; 33(7):2260-71. PubMed ID: 22189143
[TBL] [Abstract][Full Text] [Related]
12. Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer.
Fukumori T; Oka N; Takenaka Y; Nangia-Makker P; Elsamman E; Kasai T; Shono M; Kanayama HO; Ellerhorst J; Lotan R; Raz A
Cancer Res; 2006 Mar; 66(6):3114-9. PubMed ID: 16540661
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a double-CRD-mutated Gal-8 recombinant protein that retains co-stimulatory activity on antigen-specific T-cell response.
Schroeder MN; Tribulatti MV; Carabelli J; André-Leroux G; Caramelo JJ; Cattaneo V; Campetella O
Biochem J; 2016 Apr; 473(7):887-98. PubMed ID: 26795039
[TBL] [Abstract][Full Text] [Related]
14. Structural analysis of the human galectin-9 N-terminal carbohydrate recognition domain reveals unexpected properties that differ from the mouse orthologue.
Nagae M; Nishi N; Nakamura-Tsuruta S; Hirabayashi J; Wakatsuki S; Kato R
J Mol Biol; 2008 Jan; 375(1):119-35. PubMed ID: 18005988
[TBL] [Abstract][Full Text] [Related]
15. Importance of nuclear localization for the apoptosis-induced activity of a fungal galectin AAL (Agrocybe aegerita lectin).
Liang Y; Feng L; Tong X; Wang K; Li de F; Lin JC; Tang ZJ; Liu HH; Jiang S; Guo L; Wang da C; Sun H
Biochem Biophys Res Commun; 2009 Aug; 386(3):437-42. PubMed ID: 19527691
[TBL] [Abstract][Full Text] [Related]
16. Dimeric Galectin-8 induces phosphatidylserine exposure in leukocytes through polylactosamine recognition by the C-terminal domain.
Stowell SR; Arthur CM; Slanina KA; Horton JR; Smith DF; Cummings RD
J Biol Chem; 2008 Jul; 283(29):20547-59. PubMed ID: 18456665
[TBL] [Abstract][Full Text] [Related]
17. Design of a peptidic inhibitor that targets the dimer interface of a prototypic galectin.
Vladoiu MC; Labrie M; Létourneau M; Egesborg P; Gagné D; Billard É; Grosset AA; Doucet N; Chatenet D; St-Pierre Y
Oncotarget; 2015 Dec; 6(38):40970-80. PubMed ID: 26543238
[TBL] [Abstract][Full Text] [Related]
18. The N-terminal carbohydrate recognition domain of galectin-8 recognizes specific glycosphingolipids with high affinity.
Ideo H; Seko A; Ishizuka I; Yamashita K
Glycobiology; 2003 Oct; 13(10):713-23. PubMed ID: 12851289
[TBL] [Abstract][Full Text] [Related]
19. The N- and C-terminal carbohydrate recognition domains of galectin-9 contribute differently to its multiple functions in innate immunity and adaptive immunity.
Li Y; Feng J; Geng S; Geng S; Wei H; Chen G; Li X; Wang L; Wang R; Peng H; Han G; Shen B; Li Y
Mol Immunol; 2011 Jan; 48(4):670-7. PubMed ID: 21146220
[TBL] [Abstract][Full Text] [Related]
20. Stable and high expression of Galectin-8 tightly controls metastatic progression of prostate cancer.
Gentilini LD; Jaworski FM; Tiraboschi C; Pérez IG; Kotler ML; Chauchereau A; Laderach DJ; Compagno D
Oncotarget; 2017 Jul; 8(27):44654-44668. PubMed ID: 28591719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
